TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of Bosentan in Patients With Stage IV Metastatic Melanoma Treated With Dacarbazine
Brief Summary: The study is designed as a multicenter, double blind, parallel-group, placebo-controlled, randomized, event driven Phase II study of DTIC with or without bosentan as first-line treatment in patients with stage IV melanoma.


Options:
A: Arm Label: Bosentan; Type: EXPERIMENTAL; Interventions: Drug: Bosentan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): Bosentan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Inhaled treprostinil; Type: EXPERIMENTAL; Interventions: Drug: Inhaled treprostinil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo inhalation solution | Intervention Type: DRUG; Name: Inhaled treprostinil; Assigned to Arm(s): Inhaled treprostinil | Intervention Type: DRUG; Name: Placebo inhalation solution; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Arm Label: 5; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 1
D: Intervention Type: DRUG; Name: Bosentan administration; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of Bosentan in Patients With Stage IV Metastatic Melanoma Treated With Dacarbazine
Brief Summary: The study is designed as a multicenter, double blind, parallel-group, placebo-controlled, randomized, event driven Phase II study of DTIC with or without bosentan as first-line treatment in patients with stage IV melanoma.


Options:
A: Arm Label: Ambrisentan Verum; Type: EXPERIMENTAL; Interventions: Drug: Ambrisentan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ambrisentan; Assigned to Arm(s): Ambrisentan Verum | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Bosentan; Type: EXPERIMENTAL; Interventions: Drug: Bosentan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): Bosentan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Bosentan for 16 weeks; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bosentan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): Bosentan for 16 weeks | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): Bosentan for 16 weeks | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: bosentan; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of a Pre- and Postoperative Orthogeriatric Service. A Randomised, Controlled Trial
Brief Summary: The investigators' aim is to assess the effect of a model of preoperative as well as early postoperative care, treatment and rehabilitation in a dedicated orthogeriatric ward in a single-blind randomised study.

The investigators' main hypothesis is that an orthogeriatric service may improve long-time cognitive outcome.


Options:
A: Arm Label: RIPC; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Remote Ischemic Preconditioning | Arm Label: CONTROL; Type: SHAM_COMPARATOR; Interventions: Procedure: Control/sham procedure (blood pressure cuff) | Intervention Type: PROCEDURE; Name: Remote Ischemic Preconditioning; Assigned to Arm(s): RIPC | Intervention Type: PROCEDURE; Name: Control/sham procedure (blood pressure cuff); Assigned to Arm(s): CONTROL
B: Arm Label: Investigational medicinal product; Type: ACTIVE_COMPARATOR; Interventions: Drug: Haloperidol | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Haloperidol; Assigned to Arm(s): Investigational medicinal product | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo group
C: Arm Label: BIS group; Type: EXPERIMENTAL; Interventions: Device: Bispectral Index Monitor | Arm Label: MAC Alert; Type: ACTIVE_COMPARATOR; Interventions: Device: Electronic MAC alert | Intervention Type: DEVICE; Name: Bispectral Index Monitor; Assigned to Arm(s): BIS group | Intervention Type: DEVICE; Name: Electronic MAC alert; Assigned to Arm(s): MAC Alert
D: Intervention Type: PROCEDURE; Name: Orthogeriatric intervention; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of a Pre- and Postoperative Orthogeriatric Service. A Randomised, Controlled Trial
Brief Summary: The investigators' aim is to assess the effect of a model of preoperative as well as early postoperative care, treatment and rehabilitation in a dedicated orthogeriatric ward in a single-blind randomised study.

The investigators' main hypothesis is that an orthogeriatric service may improve long-time cognitive outcome.


Options:
A: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Other: Care Pathway | Intervention Type: OTHER; Name: Care Pathway; Assigned to Arm(s): Intervention group
B: Arm Label: Pathway; Type: EXPERIMENTAL; Interventions: Other: PFF evidence based pathway | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: PFF evidence based pathway; Assigned to Arm(s): Pathway
C: Intervention Type: PROCEDURE; Name: Orthogeriatric intervention; Assigned to Arm(s): N/A
D: Arm Label: Enhanced acute medical rehabilitation; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced acute medical rehabilitation | Arm Label: Treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as usual | Intervention Type: BEHAVIORAL; Name: Enhanced acute medical rehabilitation; Assigned to Arm(s): Enhanced acute medical rehabilitation | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): Treatment as usual

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of a Pre- and Postoperative Orthogeriatric Service. A Randomised, Controlled Trial
Brief Summary: The investigators' aim is to assess the effect of a model of preoperative as well as early postoperative care, treatment and rehabilitation in a dedicated orthogeriatric ward in a single-blind randomised study.

The investigators' main hypothesis is that an orthogeriatric service may improve long-time cognitive outcome.


Options:
A: Arm Label: Care as usual; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Dementia Care Management (DCM); Type: EXPERIMENTAL; Interventions: Behavioral: Dementia Care Management (DCM) | Intervention Type: BEHAVIORAL; Name: Dementia Care Management (DCM); Assigned to Arm(s): Dementia Care Management (DCM)
B: Arm Label: Liberal (10 g/dL) Transfusion Strategy; Type: EXPERIMENTAL; Interventions: Biological: Liberal (10 g/dL) Transfusion Strategy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: Restrictive (Symptomatic) Transfusion Strategy | Intervention Type: BIOLOGICAL; Name: Liberal (10 g/dL) Transfusion Strategy; Assigned to Arm(s): Liberal (10 g/dL) Transfusion Strategy | Intervention Type: BIOLOGICAL; Name: Restrictive (Symptomatic) Transfusion Strategy; Assigned to Arm(s): 2
C: Intervention Type: PROCEDURE; Name: Orthogeriatric intervention; Assigned to Arm(s): N/A
D: Arm Label: multifaceted prevention program; Type: EXPERIMENTAL; Interventions: Behavioral: Multifaceted prevention program HELP(Hospital Elder Life Program) | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Multifaceted prevention program HELP(Hospital Elder Life Program); Assigned to Arm(s): multifaceted prevention program

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52 Week Open Label Extension Study to Evaluate the Safety and Tolerability of AIN457 (Anti IL-17 Monoclonal Antibody) in Patients With Moderate to Severe Crohn's Disease
Brief Summary: This study will assess the safety and tolerability of AIN457 in patients with moderate to severe Crohn's disease who already participated and completed the core trial CAIN457A2202.


Options:
A: Arm Label: Group 1 (placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Ustekinumab 45 mg, Drug: Ustekinumab 90 mg, Drug: Golimumab 50 mg | Arm Label: Group 2 (ustekinumab 45 mg); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 45 mg, Drug: Golimumab 50 mg | Arm Label: Group 3 (ustekinumab 90 mg); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 90 mg, Drug: Golimumab 50 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 1 (placebo) | Intervention Type: DRUG; Name: Ustekinumab 45 mg; Assigned to Arm(s): Group 1 (placebo), Group 2 (ustekinumab 45 mg) | Intervention Type: DRUG; Name: Ustekinumab 90 mg; Assigned to Arm(s): Group 1 (placebo), Group 3 (ustekinumab 90 mg) | Intervention Type: DRUG; Name: Golimumab 50 mg; Assigned to Arm(s): Group 1 (placebo), Group 2 (ustekinumab 45 mg), Group 3 (ustekinumab 90 mg)
B: Arm Label: Group 1 (Placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Ustekinumab 45 mg, Drug: Ustekinumab 90 mg, Drug: Golimumab 50 mg | Arm Label: Group 2 (Ustekinumab 45 mg); Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: Ustekinumab 45 mg, Drug: Golimumab 50 mg | Arm Label: Group 3 (Ustekinumab 90 mg); Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: Ustekinumab 90 mg, Drug: Golimumab 50 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 1 (Placebo), Group 2 (Ustekinumab 45 mg), Group 3 (Ustekinumab 90 mg) | Intervention Type: DRUG; Name: Ustekinumab 45 mg; Assigned to Arm(s): Group 1 (Placebo), Group 2 (Ustekinumab 45 mg) | Intervention Type: DRUG; Name: Ustekinumab 90 mg; Assigned to Arm(s): Group 1 (Placebo), Group 3 (Ustekinumab 90 mg) | Intervention Type: DRUG; Name: Golimumab 50 mg; Assigned to Arm(s): Group 1 (Placebo), Group 2 (Ustekinumab 45 mg), Group 3 (Ustekinumab 90 mg)
C: Arm Label: Group 1: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Group 1: Placebo | Arm Label: Group 2: Ustekinumab 45 milligram (mg); Type: EXPERIMENTAL; Interventions: Drug: Group 2: Ustekinumab 45 mg | Arm Label: Group 3: Ustekinumab 90 mg; Type: EXPERIMENTAL; Interventions: Drug: Group 3: Ustekinumab 90 mg | Intervention Type: DRUG; Name: Group 1: Placebo; Assigned to Arm(s): Group 1: Placebo | Intervention Type: DRUG; Name: Group 2: Ustekinumab 45 mg; Assigned to Arm(s): Group 2: Ustekinumab 45 milligram (mg) | Intervention Type: DRUG; Name: Group 3: Ustekinumab 90 mg; Assigned to Arm(s): Group 3: Ustekinumab 90 mg
D: Arm Label: AIN457; Type: EXPERIMENTAL; Interventions: Drug: AIN457 | Intervention Type: DRUG; Name: AIN457; Assigned to Arm(s): AIN457

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: HZC102871: A 52-week Efficacy and Safety Study to Compare the Effect of Three Dosage Strengths of Fluticasone Furoate/GW642444 Inhalation Powder With GW642444 on the Annual Rate of Exacerbations in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: The Purpose of this study is to assess the efficacy and safety of three strengths of the FF/GW642444 Inhalation Powder in subject with Chronic Obstructive Pulmonary Disease (COPD)


Options:
A: Arm Label: FF/GW642444 Inhalation Powder 100/25 mcg QD; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: FF/GW642444 Inhalation Powder 200/25 mcg QD; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: FF/GW642444 Inhalation Powder 50mcg/25mcg QD; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: GW642444 25mcg QD; Type: EXPERIMENTAL; Interventions: Drug: GW642444 Inhalation Powder | Intervention Type: DRUG; Name: FF/GW642444 Inhalation Powder; Assigned to Arm(s): FF/GW642444 Inhalation Powder 100/25 mcg QD, FF/GW642444 Inhalation Powder 200/25 mcg QD, FF/GW642444 Inhalation Powder 50mcg/25mcg QD | Intervention Type: DRUG; Name: GW642444 Inhalation Powder; Assigned to Arm(s): GW642444 25mcg QD
B: Arm Label: Indacaterol 150 µg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 150 μg capsules | Arm Label: Indacaterol 300 µg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 300 μg capsules | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo capsules | Intervention Type: DRUG; Name: Indacaterol 150 μg capsules; Assigned to Arm(s): Indacaterol 150 µg | Intervention Type: DRUG; Name: Indacaterol 300 μg capsules; Assigned to Arm(s): Indacaterol 300 µg | Intervention Type: DRUG; Name: Placebo capsules; Assigned to Arm(s): Placebo
C: Arm Label: Umeclidinium/Vilanterol; Type: EXPERIMENTAL; Interventions: Drug: Umeclidinium/Vilanterol 62.5/25 mcg | Arm Label: Tiotropium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium 18 mcg | Intervention Type: DRUG; Name: Umeclidinium/Vilanterol 62.5/25 mcg; Assigned to Arm(s): Umeclidinium/Vilanterol | Intervention Type: DRUG; Name: Tiotropium 18 mcg; Assigned to Arm(s): Tiotropium
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide/Formoterol Fumarate | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide/Formoterol Fumarate | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aclidinium Bromide | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol Fumarate | Arm Label: 5; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium Bromide/Formoterol Fumarate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Aclidinium Bromide/Formoterol Fumarate; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Aclidinium Bromide; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Formoterol Fumarate; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 5

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Development and Evaluation of Electronic Feedback, a Tool for Quality Assurance of the Diabetic Care in General Practice
Brief Summary: The aim of this study is to determine whether electronic feedback to general practitioners on quality of Type 2-Diabetes care increases the quality of care measured on process and outcome measures contained in the national guidelines. Effect evaluation will be performed using a mixed method design.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Device: Electronic feedback system on diabetes care | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Electronic feedback system on diabetes care; Assigned to Arm(s): Intervention
B: Arm Label: behavioral intervention, counseling; Type: EXPERIMENTAL; Interventions: Behavioral: culturally tailored diabetes education | Arm Label: delyed intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: culturally tailored diabetes education; Assigned to Arm(s): behavioral intervention, counseling
C: Arm Label: Intervention to Patients; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention to patients, Other: Usual care | Arm Label: Intervention to healthcare Professionals; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention to professionals, Other: Usual care | Arm Label: Mixed Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention to patients, Behavioral: Intervention to professionals, Other: Usual care | Arm Label: Control; Type: OTHER; Interventions: Other: Usual care | Intervention Type: BEHAVIORAL; Name: Intervention to patients; Assigned to Arm(s): Intervention to Patients, Mixed Intervention | Intervention Type: BEHAVIORAL; Name: Intervention to professionals; Assigned to Arm(s): Intervention to healthcare Professionals, Mixed Intervention | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Control, Intervention to Patients, Intervention to healthcare Professionals, Mixed Intervention
D: Intervention Type: BEHAVIORAL; Name: Nurse Case Manager and Community Health Worker Team; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Development and Evaluation of Electronic Feedback, a Tool for Quality Assurance of the Diabetic Care in General Practice
Brief Summary: The aim of this study is to determine whether electronic feedback to general practitioners on quality of Type 2-Diabetes care increases the quality of care measured on process and outcome measures contained in the national guidelines. Effect evaluation will be performed using a mixed method design.


Options:
A: Arm Label: Telemedicine; Type: EXPERIMENTAL; Interventions: Procedure: Ophthalmic Telemedicine | Arm Label: Traditional Surveillance; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Ophthalmic Telemedicine; Assigned to Arm(s): Telemedicine
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Device: Electronic feedback system on diabetes care | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Electronic feedback system on diabetes care; Assigned to Arm(s): Intervention
C: Intervention Type: BEHAVIORAL; Name: Nurse Case Management intervention; Assigned to Arm(s): N/A
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Toolkit | Arm Label: Control; Type: OTHER; Interventions: Other: Control | Intervention Type: OTHER; Name: Toolkit; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Development and Evaluation of Electronic Feedback, a Tool for Quality Assurance of the Diabetic Care in General Practice
Brief Summary: The aim of this study is to determine whether electronic feedback to general practitioners on quality of Type 2-Diabetes care increases the quality of care measured on process and outcome measures contained in the national guidelines. Effect evaluation will be performed using a mixed method design.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Information feedback | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Information feedback | Intervention Type: BEHAVIORAL; Name: Information feedback; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Information feedback; Assigned to Arm(s): Arm 2
B: Intervention Type: BEHAVIORAL; Name: Customized Physician Intervention; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Customized Patient Intervention; Assigned to Arm(s): N/A
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Device: Electronic feedback system on diabetes care | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Electronic feedback system on diabetes care; Assigned to Arm(s): Intervention
D: Intervention Type: PROCEDURE; Name: meeting nurses / physicians, quality improvement sessions; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Compare the Efficacy of Human Albumin With Cabergoline to Prevent of Ovarian Hyper Stimulation in ART Program
Brief Summary: The purpose of this study is to investigate the efficacy and safety of cabergoline in prevention of ovarian hyperstimulation syndrome versus albumin in ART program.


Options:
A: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Norprolac | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Norprolac | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Norprolac | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Norprolac | Intervention Type: DRUG; Name: Norprolac; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Norprolac; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Norprolac; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Norprolac; Assigned to Arm(s): 4
B: Arm Label: Cabergoline group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cabergoline | Arm Label: GnRH antagonist rescue & cabergoline group; Type: EXPERIMENTAL; Interventions: Drug: GnRH antagonist rescue & cabergoline | Intervention Type: DRUG; Name: Cabergoline; Assigned to Arm(s): Cabergoline group | Intervention Type: DRUG; Name: GnRH antagonist rescue & cabergoline; Assigned to Arm(s): GnRH antagonist rescue & cabergoline group
C: Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Drug: Control | Arm Label: Cabergoline; Type: EXPERIMENTAL; Interventions: Drug: Cabergoline | Intervention Type: DRUG; Name: Cabergoline; Assigned to Arm(s): Cabergoline | Intervention Type: DRUG; Name: Control; Assigned to Arm(s): Control
D: Arm Label: Coasting; Type: ACTIVE_COMPARATOR; Interventions: Procedure: ICSI | Arm Label: Cabergoline; Type: ACTIVE_COMPARATOR; Interventions: Procedure: ICSI | Arm Label: Coasting and Cabergoline; Type: ACTIVE_COMPARATOR; Interventions: Procedure: ICSI | Intervention Type: PROCEDURE; Name: ICSI; Assigned to Arm(s): Cabergoline, Coasting, Coasting and Cabergoline

Answer: C